A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

Background: Hypertriglyceridaemia is common in patients with HIV, especially those taking protease inhibitors or with lipodystrophy, frequently observed at levels associated with accelerated cardiac disease. This study aimed to explore the efficacy and safety of gemfibrozil for hypertriglyceridemia in patients with HIV infection. Methods: A 16-week, randomized, double-blind, comparative study of low saturated fat diet versus low saturated fat diet with gemfibrozil 600 mg twice daily in patients with triglycerides ⩾ 3mmol/l receiving protease inhibitor therapy. Following a 4-week period of dietary intervention alone, patients were randomized to gemfibrozil or matching placebo. The primary outcome was the difference in mean change in fasting triglycerides at week 16 between the two groups. Results: 37 men were randomized (17 gemfibrozil, 20 placebo) with median fasting triglycerides 5.6 mmol/l. Mean changes in triglycerides from week 4 to week 16 were –1.22 mmol/l and +0.35 mmol/l for the gemfibrozil and placebo groups respectively (between-group mean difference of 1.57 mmol/l; 95% confidence interval, –6.7 to 3.5; P = 0.08). Only one patient treated had triglycerides return to a desirable range (⩽ 2.00 mmol/l). No significant changes in the other metabolic parameters were observed. Gemfibrozil was well tolerated, did not appear to induce additional protease inhibitor toxicity, and did not induce changes in CD4 lymphocyte counts or HIV RNA load. Conclusions: Gemfibrozil is safe and demonstrated at most, modest efficacy for hypertriglyceridemia in HIV-infected patients receiving protease inhibitors. Given the level of response, however, it is unclear whether these reductions will confer clinical benefit, at least in the presence of continued protease inhibitor use.

[1]  J. Mallolas,et al.  Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Tuomilehto,et al.  Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. , 2009, Acta medica Scandinavica. Supplementum.

[3]  J. Feely,et al.  The impact of HIV disease progression on serum lipoproteins. , 1992, AIDS.

[4]  J. Wang,et al.  Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[5]  H. Rodbard,et al.  The American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis , 2000 .

[6]  G. Rosenhamer,et al.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.

[7]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[8]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[9]  R. D'Agostino,et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Telenti,et al.  Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. , 2001, Journal of acquired immune deficiency syndromes.

[11]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[12]  V. Soriano,et al.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy , 2000, AIDS.

[13]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[14]  K. Henry,et al.  Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities , 1998, The Lancet.

[15]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[16]  J. Gatell,et al.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.

[17]  J. Viallard,et al.  Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. , 2000, European journal of internal medicine.

[18]  S. Mallal,et al.  HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study , 2001, AIDS.

[19]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.